HLB Co., Ltd. (028300.KQ)
KRW 70500.0
(-1.26%)
KRW 70500.0
(-1.26%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 169.47 Billion KRW | -36.83% |
| 2022 | 268.28 Billion KRW | 15.89% |
| 2021 | 231.5 Billion KRW | 55.32% |
| 2020 | 149.04 Billion KRW | -14.03% |
| 2019 | 173.36 Billion KRW | 83.43% |
| 2018 | 94.51 Billion KRW | 26.84% |
| 2017 | 74.51 Billion KRW | 18.97% |
| 2016 | 62.63 Billion KRW | -11.51% |
| 2015 | 70.78 Billion KRW | 126.64% |
| 2014 | 31.23 Billion KRW | 51.6% |
| 2013 | 20.6 Billion KRW | -27.45% |
| 2012 | 28.39 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 210.69 Billion KRW | 24.32% |
| 2024 Q2 | 221.7 Billion KRW | 5.23% |
| 2023 Q3 | 199.47 Billion KRW | -12.76% |
| 2023 Q2 | 228.63 Billion KRW | -5.06% |
| 2023 FY | 169.47 Billion KRW | -36.83% |
| 2023 Q1 | 240.81 Billion KRW | -10.24% |
| 2023 Q4 | 169.47 Billion KRW | -15.04% |
| 2022 Q4 | 268.28 Billion KRW | -7.7% |
| 2022 Q3 | 290.67 Billion KRW | 4.62% |
| 2022 Q2 | 277.82 Billion KRW | 7.61% |
| 2022 Q1 | 258.17 Billion KRW | 11.52% |
| 2022 FY | 268.28 Billion KRW | 15.89% |
| 2021 Q4 | 231.5 Billion KRW | 71.77% |
| 2021 Q2 | 145.83 Billion KRW | 0.34% |
| 2021 FY | 231.5 Billion KRW | 55.32% |
| 2021 Q1 | 145.34 Billion KRW | -2.49% |
| 2021 Q3 | 134.77 Billion KRW | -7.58% |
| 2020 Q1 | 159.84 Billion KRW | -7.8% |
| 2020 FY | 149.04 Billion KRW | -14.03% |
| 2020 Q2 | 140.84 Billion KRW | -11.89% |
| 2020 Q3 | 143.4 Billion KRW | 1.81% |
| 2020 Q4 | 149.04 Billion KRW | 3.94% |
| 2019 Q1 | 107.53 Billion KRW | 13.78% |
| 2019 Q2 | 133.61 Billion KRW | 24.25% |
| 2019 FY | 173.36 Billion KRW | 83.43% |
| 2019 Q4 | 173.36 Billion KRW | 19.58% |
| 2019 Q3 | 144.97 Billion KRW | 8.5% |
| 2018 Q1 | 89.59 Billion KRW | 20.24% |
| 2018 Q4 | 94.51 Billion KRW | 18.4% |
| 2018 Q3 | 79.82 Billion KRW | -28.99% |
| 2018 Q2 | 112.41 Billion KRW | 25.47% |
| 2018 FY | 94.51 Billion KRW | 26.84% |
| 2017 Q4 | 74.51 Billion KRW | -12.8% |
| 2017 FY | 74.51 Billion KRW | 18.97% |
| 2017 Q1 | 62.21 Billion KRW | -0.68% |
| 2017 Q2 | 64.05 Billion KRW | 2.97% |
| 2017 Q3 | 85.45 Billion KRW | 33.4% |
| 2016 Q3 | 60.66 Billion KRW | -2.4% |
| 2016 FY | 62.63 Billion KRW | -11.51% |
| 2016 Q4 | 62.63 Billion KRW | 3.24% |
| 2016 Q2 | 62.15 Billion KRW | 1.12% |
| 2016 Q1 | 61.47 Billion KRW | -13.15% |
| 2015 Q1 | 31.09 Billion KRW | -0.45% |
| 2015 Q4 | 70.78 Billion KRW | 221.0% |
| 2015 FY | 70.78 Billion KRW | 126.64% |
| 2015 Q2 | 22.54 Billion KRW | -27.5% |
| 2015 Q3 | 22.05 Billion KRW | -2.17% |
| 2014 Q4 | 31.23 Billion KRW | 17.53% |
| 2014 Q3 | 26.57 Billion KRW | 6.66% |
| 2014 Q2 | 24.91 Billion KRW | -4.0% |
| 2014 Q1 | 25.95 Billion KRW | 25.98% |
| 2014 FY | 31.23 Billion KRW | 51.6% |
| 2013 Q4 | 20.6 Billion KRW | -2.19% |
| 2013 FY | 20.6 Billion KRW | -27.45% |
| 2013 Q1 | 28.3 Billion KRW | -0.31% |
| 2013 Q3 | 21.06 Billion KRW | -16.92% |
| 2013 Q2 | 25.35 Billion KRW | -10.44% |
| 2012 Q4 | 28.39 Billion KRW | 0.0% |
| 2012 FY | 28.39 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -8912.902% |
| BINEX Co., Ltd. | 75.68 Billion KRW | -123.919% |
| Bioneer Corporation | 80.61 Billion KRW | -110.24% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -747.938% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | -24.857% |
| CrystalGenomics, Inc. | 97.82 Billion USD | -73.248% |
| Helixmith Co., Ltd | 73.55 Billion KRW | -130.398% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 84.15% |
| Medy-Tox Inc. | 137.14 Billion KRW | -23.578% |
| Peptron, Inc. | 16.36 Billion KRW | -935.345% |
| Amicogen, Inc. | 248.12 Billion KRW | 31.697% |
| Genexine, Inc. | 79.68 Billion KRW | -112.687% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -478.888% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -310.541% |
| ALTEOGEN Inc. | 108.25 Billion KRW | -56.547% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | -131.883% |
| SillaJen, Inc. | 19.4 Billion KRW | -773.541% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 5.369% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | -222.877% |
| Genomictree Inc. | 7.81 Billion KRW | -2069.348% |
| MedPacto, Inc. | 9.56 Billion KRW | -1671.693% |
| D&D Pharmatech | 23.98 Billion KRW | -606.569% |
| EASY BIO,Inc. | 105.86 Billion KRW | -60.081% |
| GI Innovation, Inc. | 9.63 Billion KRW | -1658.735% |